Episode 116: AML Series, Pt. 2 - MDS/AML Diagnosis and Risk Stratification

Episode 116: AML Series, Pt. 2 - MDS/AML Diag...

Up next

Episode 147: Myeloma Series, Pt. 7 - Transplant Consolidation for Multiple Myeloma (2026)

This week, we discuss the role of the “consolidation” phase of treatment in multiple myeloma, focusing on three key trials: IFM 2009, DETERMINATION, and the MIDAS Trial.Content:- What is the role of autologous stem cell transplant in the management of multiple myeloma? - How did ...  Show more

Episode 146: Career Development Series-Choosing Your Ideal Mentor

This week, we are so excited to share the first of our Career Development Series episodes, developed in partnership with The American Society of Hematology , The ASH Trainee Council, and Hematopoiesis! For years, our listeners have reached out to our show asking for guidance to h ...  Show more

Recommended Episodes

#58 Rheumatoid arthritis (part 1)
Pre PACES Podcast

Consultant Rheumatologist and co-host of the Medical Take podcast, Dr Arrian ...

  Show more

143. San Antonio Breast Cancer Symposium 2024 - Part 2
Oncology for the Inquisitive Mind

Our second SABCS (San Antonio Breast Cancer Symposium) episode covers everything (else) you need to know from 2024.


In this episode, we dive into the role of trastuzumab deruxtecan in HR +ve, HER2 low cancers, perioperative atezolizumab in tnbc, the use of a novel A ...

  Show more

3290: Coros Pace 3 vs. Apple Watch Review, Dostarlimab and Endometrial & Colorectal Cancer Research (FR)
The Cabral Concept

<div><span class= "author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qowz82zpfz80zz75zz76zz88znwz72zz80zz89zz82zg1z84zvz79zz81zrl5z84zz90zz86zxlgz73zz76zn"> Welcome back to today's Friday Review where I'll be breaking down the best of the week!</span></div> <div> </div> <div> </div> <div><s ...  Show more

Survivorship
Ready, Set, GYO!

This is the last episode of our core curriculum series. In this episode we discuss cancer survivorship as it relates to gynecologic oncology. Additionally we provide a framework for surveillance visits as well the general timing based on primary malignancy. We also give a brief o ...  Show more